文献速递生殖医学产科母胎医学

体外成熟卵母细胞辅助生殖后母婴结局与子代发育的系统综述与荟萃分析

Maternal and neonatal outcome and children's development after medically assisted reproduction with in-vitro matured oocytes-a systematic review and meta-analysis.
PubMed 文献 · Hum Reprod Update · 2021-01-01

该系统综述纳入16项研究,评估体外成熟(IVM)卵母细胞辅助生殖对子代出生体重、2岁内发育及母婴结局的影响。结果显示IVM子代出生体重、畸形率及2岁时体格与精神发育与常规刺激(COS)或自然妊娠子代相当,但PCOS女性IVM单胎妊娠高血压疾病显著更常见。

要点

  • IVM子代出生体重、畸形率及2岁内发育与COS或自然妊娠子代无显著差异。
  • PCOS女性IVM单胎妊娠高血压疾病显著多于COS,尤其仅用体外成熟卵母细胞周期。
  • IVM与COS单胎妊娠的妊娠期糖尿病和早产率无差异,无论是否使用排卵触发。

核心结论

  • IVM子代出生体重、畸形率及2岁内发育与COS或自然妊娠子代相当。
  • PCOS女性IVM单胎妊娠高血压疾病显著更常见,需孕期监测。

研究设计与样本

  • 系统综述与荟萃分析,检索Google Scholar和PubMed至2020年1月,筛选191项研究,最终纳入16项进行定性合成。
  • 研究按指征、排卵触发使用及多胎性分层。

主要发现

  • IVM单胎和多胎出生体重与各自COS对照相当,限制于PCOS母亲时也相似。
  • IVM子代出生体重与COS子代相当,无论IVM周期是否使用排卵触发。
  • 单胎妊娠妊娠期糖尿病频率在IVM与COS间相当,无论不孕背景或hCG排卵触发使用与否。
  • PCOS女性单胎妊娠高血压疾病在IVM后显著更频繁,尤其仅用体外成熟卵母细胞周期。
  • 单胎早产率在IVM与COS间无差异,仅比较PCOS女性或考虑排卵触发使用时仍相似。

关键数值与推荐

  • 主要结局参数为出生体重和子代至2岁发育。
  • 次要结局参数为妊娠病理及IVM与COS子代结局,按母亲指征(尤其PCOS)和IVM方案(有无排卵触发)比较。

临床怎么用

  • IVM后妊娠需监测高血压疾病,尤其PCOS女性。
  • 当前IVM子代发育数据令人鼓舞,但研究质量有限且2年后长期数据缺乏。

局限性

  • 许多研究质量有限。
  • 超过2岁的长期数据稀缺。
  • IVM方案不统一,研究设计难以比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: IVM was implemented in medically assisted reproduction 25 years ago. IVM does not involve controlled ovarian stimulation (COS) and is mainly indicated in patients with a high risk of ovarian hyperstimulation syndrome, in particular in patients with polycystic ovary syndrome (PCOS); it is also an acknowledged option in fertility protection. However, the in-vitro culture of immature oocytes raises concerns over their developmental potential and the putative impact on children's health. Although an increasing number of studies on obstetric and neonatal outcomes of IVM children and their development have been published in recent years, study designs are difficult to compare, since IVM is used in women with various indications and IVM protocols do not follow the same standards. OBJECTIVE AND RATIONALE: The aim of this systematic review was to evaluate the current evidence from IVM children of an impact of in-vitro culture of immature oocytes. Primary outcome parameters were birthweight and children's development up to the age of 2 years. We also compared pregnancy pathologies and the outcome of IVM children and COS children in relation to maternal indications, in particular PCOS, and to the type of IVM protocols with or without ovulation trigger as the secondary outcome parameters. IVM is an accepted clinical option for many centres; however, a comprehensive analysis of the available data is needed to establish whether the use of human oocytes that are fully matured in vitro is safe for both children and their mothers. SEARCH METHODS: Google Scholar and PubMed were used for identifying peer-reviewed original articles and reviews through January 2020. A total of 191 studies were screened and 16 studies were included in the qualitative synthesis. Studies were stratified according to indications, the use of an ovulation trigger and multiplicity. OUTCOMES: Birthweights of IVM singletons and multiples were comparable to their respective COS controls: birthweights were also similar if the analysis was restricted to mothers with PCOS. IVM children had a comparable birthweight to COS children, irrespective of whether an ovulation trigger was used in IVM cycles or not. The frequency of gestational diabetes (GD) in singleton pregnancies was comparable between IVM and COS, regardless of infertility background. There was also no difference in GD frequency between IVM and COS, if an hCG ovulation trigger in IVM cycles was used or not. Hypertensive disorders in singleton pregnancies of women with PCOS were significantly more frequent after IVM compared to COS, in particular if IVM cycles were performed only with in-vitro matured oocytes. There was no difference in the preterm birth rate of singleton pregnancies between IVM and COS. Preterm birth rates were still similar if only women diagnosed with PCOS were compared and whether an ovulation trigger in IVM was used or not. The malformation rate in IVM children did not differ in COS children versus children after natural conception. At the age of 2 years, IVM singletons showed similar anthropometric and mental development compared to COS children or children from natural conception. WIDER IMPLICATIONS: The higher incidence of hypertensive disorders in IVM pregnancies needs monitoring during pregnancy. Current data on the development of IVM children are encouraging, although the quality of many studies is limited and long-term data beyond 2 years are scarce. Further studies should be based on generally accepted IVM protocols. Studies on long-term outcomes beyond 2 years are needed to search for potential long-time sequelae of IVM.

来源:Hum Reprod Update,查看原文。版权归原作者所有。

引用

  1. Strowitzki T, Bruckner T, Roesner S, et al. Maternal and neonatal outcome and children's development after medically assisted reproduction with in-vitro matured oocytes-a systematic review and meta-analysis. Hum Reprod Update. 2021. PMID: 33377477. doi:10.1093/humupd/dmaa056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。